Results of a Clinical Trial on Riamilovir for COVID-19 Treatment
Published in Ter Arkh, June 2024
AIM: To assess the effectiveness and safety of riamilovir in treating COVID-19 in adults.
MATERIALS AND METHODS: The study involved 180 adult patients with confirmed COVID-19 who met specific criteria and provided informed consent.
RESULTS: The clinical trial confirmed the efficacy, good tolerability, and safety of riamilovir in treating COVID-19.
CONCLUSION: The multicenter trial established the effectiveness of riamilovir at a daily dose of 1250 mg for 10 days in treating COVID-19. This dosage was found to be as safe as a placebo.
Value: Clinical trials are essential for developing safe treatments, and our AI-driven platform, DocSym, consolidates medical standards and research for easy access. Our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining healthcare operations and improving patient care.
Practical Solutions: By leveraging AI, clinics can enhance workflows, reduce paperwork, and improve patient outcomes. Learn more about our solutions at aidevmd.com.
